Lorlatinib is very successful in treating ALK-positive non-small cell lung cancer, according to a phase III trial.

Published Date: 05 Jun 2024

Through a phase III clinical trial, a large group of physicians and researchers discovered that lorlatinib, an ALK inhibitor, is very effective in treating non-small cell lung cancer (NSCLC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

2.

Error on the MGUS-Autoimmune Disease Association.

3.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

4.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

5.

Unified Neuro/Psych Residency Program: New Proposal.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot